Charles River Laboratories International, Inc. $CRL Stock Sold by Investment House LLC

Investment House LLC lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 62.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 9,084 shares of the medical research company’s stock after selling 14,934 shares during the quarter. Investment House LLC’s holdings in Charles River Laboratories International were worth $2,680,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of CRL. Physician Wealth Advisors Inc. grew its holdings in shares of Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Continuum Advisory LLC bought a new stake in Charles River Laboratories International during the second quarter worth $30,000. IFP Advisors Inc lifted its holdings in Charles River Laboratories International by 182.8% during the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after acquiring an additional 106 shares during the period. Activest Wealth Management boosted its position in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the last quarter. Finally, Hilltop National Bank boosted its position in Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock worth $129,000 after purchasing an additional 127 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 4,179 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares of the company’s stock, valued at $7,788,017.16. The trade was a 12.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the transaction, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 91,971 shares of company stock worth $26,033,968. Company insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on CRL shares. Morgan Stanley upped their price objective on Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Finally, Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research report on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $302.33.

Charles River Laboratories International Trading Down 1.2%

Shares of CRL opened at $340.64 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $351.21. The business has a 50-day moving average of $293.05 and a 200 day moving average of $232.43. The firm has a market cap of $16.26 billion, a P/E ratio of -70.24, a price-to-earnings-growth ratio of 3.22 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.